Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Spyre Therapeutics is a clinical-stage biotechnology company developing targeted therapies for cancer and autoimmune diseases, with a focus on novel small molecule inhibitors. The company has no commercial revenue and is entirely dependent on clinical trial execution, regulatory milestones, and capital markets access. Stock performance is driven by clinical data readouts, partnership announcements, and biotech sector sentiment.
As a clinical-stage biotech, Spyre operates on a binary outcome model: invest capital in R&D to advance drug candidates through clinical trials, seek regulatory approval, then monetize through direct commercialization or partnerships. Value creation depends on demonstrating clinical efficacy, safety profiles superior to existing treatments, and navigating FDA approval processes. The company's $2.2B market cap with zero revenue reflects investor expectations for future pipeline success, discounted for clinical and regulatory risk. Current cash runway (evidenced by 10.90x current ratio and ~$200M annual cash burn) provides operational flexibility through multiple clinical catalysts.
Clinical trial data readouts - efficacy endpoints, safety profiles, and statistical significance versus placebo or standard-of-care comparators
FDA regulatory interactions - IND clearances, breakthrough therapy designations, Fast Track status, or clinical hold notifications
Partnership and licensing deals - upfront payments, milestone structures, and royalty rates with larger pharmaceutical companies
Capital raises and cash runway extensions - equity offerings, debt financings, or non-dilutive funding that extend operational timeline
Competitive clinical data from rival programs targeting similar indications or mechanisms of action
Binary clinical trial outcomes - single Phase 2/3 failure can eliminate 50-90% of market value overnight as pipeline value concentrates in lead programs
Regulatory approval uncertainty - FDA requirements evolving, potential for clinical holds, additional trial requirements, or outright rejections extending timelines by years
Capital markets dependence - with $200M annual cash burn and no revenue, company requires continued access to equity/debt markets; adverse conditions could force asset sales or unfavorable partnerships
Mechanism-of-action competition - rival biotechs and Big Pharma developing therapies targeting same pathways or indications could demonstrate superior efficacy or reach market first
Standard-of-care evolution - breakthrough therapies from competitors could raise efficacy bar or eliminate addressable patient populations before Spyre reaches commercialization
Cash runway constraints - current burn rate implies 12-18 month runway requiring near-term financing; dilutive equity raises at unfavorable valuations could significantly impact existing shareholders
Negative equity generation - -31.2% ROE and -29.5% ROA reflect ongoing losses typical of clinical stage but create balance sheet pressure if cash reserves deplete faster than anticipated
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as they have no commercial operations. However, severe recessions can impact: (1) capital markets access for future financings, (2) partnership appetite from Big Pharma, and (3) healthcare system capacity for clinical trial execution. The 116.6% six-month return suggests strong risk-on sentiment benefiting speculative growth assets.
High sensitivity through valuation multiples rather than operations. Clinical-stage biotechs are long-duration assets (cash flows 5-10+ years out) making them highly sensitive to discount rate changes. Rising rates compress NPV of future product revenues and make risk-free alternatives more attractive, typically contracting biotech valuations. The 6.0x price-to-book ratio reflects significant intangible value vulnerable to rate-driven multiple compression. Lower rates benefit through: (1) higher valuation multiples for growth stocks, (2) easier equity financing conditions, (3) increased M&A activity from cash-rich acquirers.
Minimal direct credit exposure given zero debt (0.00 Debt/Equity) and strong liquidity (10.90x current ratio). However, credit market conditions indirectly impact: (1) convertible debt financing availability as alternative to dilutive equity, (2) venture debt access for non-dilutive runway extension, (3) Big Pharma partnership activity which correlates with corporate credit conditions. Widening high-yield spreads typically signal risk-off sentiment that pressures speculative biotech valuations.
growth - Pure speculation on clinical success with no current cash flows attracts risk-tolerant growth investors, biotech-focused funds, and momentum traders. The 66.3% one-year return and 116.6% six-month surge indicate strong momentum investor participation. Not suitable for value (no earnings/cash flow to value) or dividend investors (no distributions). Institutional ownership likely includes specialized healthcare/biotech funds rather than broad index investors.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial data, FDA decisions). Single-day moves of 30-50% common on material news. The 52.3% three-month return demonstrates elevated volatility typical of pre-revenue biotech. Beta likely exceeds 1.5-2.0x relative to broader market, with idiosyncratic risk dominating systematic risk.
